Avantium came into today trading around €5 after a rough 90 days where the stock fell about 31% and expectations had already cooled. The headline from this half year is not top line momentum. It is the deepening loss, with H1 2026 net income excluding extra items coming in at a loss of €22.1 million on just €8.3 million of revenue.
For a high valuation growth story trading on a P/S near 8.7x, that kind of profit squeeze can affect sentiment quickly, even if the longer term sales narrative still attracts investors.
Love the long term Avantium growth pitch but worried about deep losses on a rich P/S multiple? Take a look at our 224 resilient stocks with low risk scores for ideas that pair stronger balance sheets with lower risk profiles.
Prefer clean visuals instead of another wall of earnings tables and raw figures? View Avantium's full financial picture, including a clear summary of its recent losses and revenue base, in the company report for Avantium.
For anyone backing Avantium as an ESG aligned materials play, the revenue line offers the clearest support. Sales in H1 2026 reached €8.257 million compared with €6.688 million a year earlier, so customers are still engaging with the portfolio. The share price also finished September slightly higher over 7 and 30 days, which suggests the market did not immediately punish the stock further after these results, despite the deep loss. For a long runway commercialisation story, that combination of a growing top line and stabilising short term price action matters.
The other side of the ledger is tough. Avantium reported a net loss excluding extra items of €22.142 million for H1 2026 versus €9.376 million in the prior period, and trailing 12 month losses widened to €35.284 million. That kind of cash drain reinforces concerns about capital intensity and funding needs for bio based chemistry projects. The stock is still down about 31% over 90 days, which shows investors continue to treat the earnings profile cautiously, even with recent price stabilisation.
Compare Avantium's growing revenue line and deepening losses with where institutional forecasts are heading. See the consensus price target analysis for AvantiumAvantium's mix of deeper recent losses and a high P/S multiple makes timing matter, so register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and wait for a setup that suits your plan. When you do decide to take a position, use the Portfolio Command Center to cut through noise and focus on the updates that actually affect your thesis. For a longer view, tap into crowd thinking through the Community and see how other investors are reacting to the same data. That combination helps you surface potential catalysts or red flags early and stay a step ahead of the wider market.
Fresh ideas move first. While attention sits on Avantium, other themes may already be building breakout momentum under the radar for now. Do not get caught reacting late, act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com